Pfizer Inc. $PFE Shares Acquired by Wealthfront Advisers LLC

Wealthfront Advisers LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 19.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 824,349 shares of the biopharmaceutical company’s stock after buying an additional 134,523 shares during the quarter. Wealthfront Advisers LLC’s holdings in Pfizer were worth $23,148,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. increased its position in Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares during the last quarter. State Street Corp raised its stake in Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Pfizer by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after purchasing an additional 1,184,728 shares during the last quarter. Morgan Stanley grew its stake in shares of Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after buying an additional 14,342,946 shares during the period. Finally, Norges Bank purchased a new stake in shares of Pfizer during the 4th quarter valued at $1,830,986,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 2.1%

NYSE PFE opened at $24.77 on Thursday. The stock has a market cap of $141.18 billion, a P/E ratio of 18.91 and a beta of 0.35. The company’s fifty day simple moving average is $25.25 and its 200-day simple moving average is $26.18. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced FDA approval for PADCEV plus Keytruda in muscle-invasive bladder cancer, expanding the platinum-free regimen to a broader patient group and strengthening Pfizer’s oncology franchise. Pfizer Announces FDA Approval of PADCEV plus Keytruda in MIBC
• Positive Sentiment: Several recent articles point to upside potential for PFE, citing Wall Street price targets above the current trading range and highlighting potential benefits from Seagen integration and oncology growth. Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
• Positive Sentiment: Pfizer remains attractive to income investors thanks to its high dividend yield, which continues to support the stock’s value case even as investors wait for stronger earnings growth. Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?
• Neutral Sentiment: Analysts are watching Pfizer’s upcoming Q2 results closely, with expectations for a profit decline but possible offsets from cancer drugs, biosimilars, and pipeline updates. Here’s How Pfizer’s Oncology Growth Story Looks Ahead of Q2 Results
• Negative Sentiment: Some coverage still emphasizes pressure on earnings and the market’s cautious stance toward Pfizer ahead of results, suggesting investors remain concerned about near-term profit trends. Here’s What to Expect From Pfizer’s Next Earnings Report

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. Wolfe Research reiterated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. JPMorgan Chase & Co. cut their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Citigroup lifted their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Finally, Guggenheim decreased their target price on Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.50.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.